Endocrine Abstracts

The purpose of this study is to assess the treatment outcome of pregnant patients with Graves-Basedow disease. In the period of 20 years 59 pregnancies in hyperthyroid patients were registered with Graves-Basedow disease in the Department of Nuclear Medicine in Clinical Hospital Bitola. Thyrostatic therapy was applied in 29 (56.5%) pregnant patients divided into 2 groups. The first group were patients who used methimazole therapy (MMT) or 50–400 mg propiltiuracil (PTU). Of this group, 19 were born healthy infants (74.3%), 2 (5.12) with low birth weight, 5 (12.8) were premature but with no fetal malformations. The second group were patients who were not regularly controlled and treated. Of them all three babies were born with malformations (two newborns died shortly after birth and one newborn died six months after birth).

Conclusion: Our study suggests that patients treated with Graves-Basedow disease during pregnancy with a low dose of thyrostatic therapy, provides a significant reduction of fetal complications. Our study also indicated no significant difference in the effects of both drugs - PTU and MMT in these doses although preferably PTU because of reduced transplancental passage compared to MMT. In our study observed complications and mortality in newborns of mothers with uncontrolled or inadequate and irregular treated hyperthyroidism.